SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
SG Americas Securities LLC reduced its stake in Syndax Pharmaceuticals by 70.2% in Q1, now holding 38,548 shares worth $900,000. Despite this, the company has an average "Moderate Buy" rating, although some analysts like Weiss Ratings maintain a "sell." Recent insider selling by key executives and mixed Q1 results (EPS beat, revenue missed) add complexity to the stock's outlook.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement grants to eight new employees for up to 250,700 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a portion vesting on the one-year anniversary and the remainder monthly thereafter, contingent on continued employment. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced it granted inducement awards to eight new employees to purchase up to 250,700 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a staggered vesting schedule. The company, a commercial-stage biopharmaceutical entity, is focused on advancing innovative cancer therapies, including its FDA-approved drugs Revuforj and Niktimvo.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts
Syndax Pharmaceuticals (NASDAQ:SNDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $42.55. Recent analyst updates include price target increases from JPMorgan, Barclays, and Goldman Sachs, though Wall Street Zen downgraded the stock to "hold." Insider selling by CEO Michael A. Metzger and CMO Nicholas A.J. Botwood was noted, while institutional investors like Vanguard and Bank of America increased their stakes.
Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3
This article provides financial information for Syndax Pharmaceuticals Inc, listed on the Stuttgart Stock Exchange under the ticker SWB:1T3. It specifically highlights the "Purchase/sale of business (net)" data, indicating that currently, there are no recorded values for this metric. The page includes standard financial disclaimers and copyright information for the data providers.
Price to sales forward of Syndax Pharmaceuticals Inc – MUN:1T3
This article provides the "Price to sales forward" metric for Syndax Pharmaceuticals Inc (MUN:1T3) on the Munich Stock Exchange. It appears to be a stub or a section focused solely on this financial data point, without further detail or analysis. The content is presented within the context of a TradingView page for the company.
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has been removed from the Russell 2000 Value Benchmark. This news comes amidst recent positive data reports for its leukemia combo drug trial and other corporate announcements regarding convertible senior notes and abstract acceptances for medical conferences. The company is a commercial-stage biopharmaceutical firm focused on developing cancer therapies like Revuforj and Niktimvo.
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has been removed from the Russell Small Cap Comp Value Benchmark. The announcement was made by S&P Capital IQ. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing cancer therapies.
Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX
The article provides a financial overview for Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), focusing on its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data page, showing market statistics and product offerings from TradingView.
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has been removed from the Russell 3000 Value Benchmark. The company is a commercial-stage biopharmaceutical firm focused on developing cancer therapies, with product candidates like Revuforj for acute leukemias and Niktimvo for chronic graft-versus-host disease. Analysts currently hold a 'BUY' consensus rating for SNDX, with an average target price significantly above its last closing price.
Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative?
Syndax Pharmaceuticals (SNDX) was removed from several Russell value indexes on June 27, 2026, which could impact its liquidity and ownership patterns. While this index removal poses fresh questions about sentiment, the core investment narrative remains focused on the clinical and regulatory success of its drugs, Revuforj and Niktimvo, particularly the promising SAVE trial data for Revuforj in AML. Despite potential changes in the shareholder base, the company's long-term value continues to be driven by its drug development milestones rather than index inclusion.
Enterprise value to EBITDA forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX
This article displays the "Enterprise value to EBITDA forward" for Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) on TradingView. It provides a specific financial metric for the company, accessible through the platform's financial tools. The content itself seems to be a snapshot from a financial data provider, showing the value and any changes for this particular metric.
Trading the Move, Not the Narrative: (SNDX) Edition
This article provides an AI-driven analysis for Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting strong sentiment across all horizons and an exceptional risk-reward setup. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, showing strong signals for near-term, mid-term, and long-term horizons.
Price to earnings forward of Syndax Pharmaceuticals Inc – DUS:1T3
This article provides financial information for Syndax Pharmaceuticals Inc (DUS:1T3) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The site primarily serves as a financial data platform offering various tools and resources related to market analysis.
Price to book forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX
The article provides a financial metric, the "Price to book forward," for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX). It indicates that the market was closed at the time of publication and no trades were made. The content is primarily a data point presented within a financial platform context.
Price to sales forward of Syndax Pharmaceuticals Inc – DUS:1T3
This article provides the "Price to sales forward" financial data for Syndax Pharmaceuticals Inc (DUS:1T3). The content appears to be a stub or a section from a larger financial data platform, showing the company name, stock exchange, and relevant financial metric. No specific values or detailed analysis are presented in this excerpt.
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright has reiterated its Buy rating for Syndax Pharmaceuticals (SNDX.US), maintaining a target price of $40. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Syndax Pharmaceuticals Inc Actuals & Estimates (DUS:1T3)
This article provides an overview of Syndax Pharmaceuticals Inc (DUS:1T3) financial actuals and estimates, including income statement, balance sheet, and cash flow data. It covers analyst forecasts for the stock price, historical highs and lows, upcoming earnings dates, and detailed financial figures like EPS, revenue, and net income. The article also confirms that the company does not pay dividends and details its employee count and EBITDA.
SNDX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Syndax Pharmaceuticals, Inc. (SNDX) stock, including current market data, analyst price targets, and historical performance. It details the company's financials, future earnings reports, and answers frequently asked questions about its stock. The article also offers a disclaimer that the information is not investment advice.
Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data
Syndax Pharmaceuticals (SNDX) is gaining attention after its Phase 1/2 SAVE trial data for an all-oral regimen in relapsed or refractory acute myeloid leukemia was released. Despite a 100% shareholder return over the past year, the stock has seen a 21% drop in the last 90 days, with its current price at $19.00. The company is considered 51.9% undervalued according to most narratives, with a fair value estimated around $39.50, driven by late-stage pipeline advancements and strong clinical data in precision oncology.
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Syndax Pharmaceuticals Inc (SNDX), noting its current valuation score of 7.45, which ranks 216 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -7.02, indicating it is significantly below its recent high. The report also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data
Syndax Pharmaceuticals (SNDX) is gaining attention after new data from its Phase 1/2 SAVE trial for acute myeloid leukemia, leading to a narrative that the stock is 51.9% undervalued with a fair value of $39.50 compared to its current price of $19.00. While the company shows strong long-term growth potential due to its pipeline and market position, this valuation relies heavily on the success of its two late-stage drugs, introducing clinical and regulatory risks. Investors are advised to review the underlying data to determine their stance.
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary
This article summarizes Syndax Pharmaceuticals' presentation at the TD Cowen 46th Annual Health Care Conference. It highlights the success of their two commercial hematology products, Revuforj and Niktimvo, which have achieved significant market penetration and sales. The company is well-capitalized with $400 million in cash and expects continued growth through new indications and expanded market opportunities for both drugs.
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Catalio Capital Management LP
Catalio Capital Management LP significantly reduced its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 25.9% in the fourth quarter of 2025, selling 417,910 shares. Despite this, several other major institutional investors like Vanguard, Goldman Sachs, and State Street increased their holdings in the company. Syndax Pharmaceuticals reported a quarterly EPS of -$0.48, beating estimates, but revenue fell short, and the company remains unprofitable.
Apis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX
Apis Capital Advisors LLC increased its stake in Syndax Pharmaceuticals by 13.5% in the fourth quarter, purchasing an additional 86,000 shares to bring its total holdings to 724,000 shares valued at approximately $15.2 million. Syndax Pharmaceuticals reported better-than-expected quarterly earnings, though revenue fell short of estimates, and the company's stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $42.55. Despite positive analyst sentiment, recent insider selling by the CMO and CEO has been noted.
Eversept Partners LP Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Eversept Partners LP slightly reduced its stake in Syndax Pharmaceuticals Inc. by 4.4% in the fourth quarter, though the company still remains a significant holding for the fund. Despite continued insider selling by CMO Nicholas A.J. Botwood and CEO Michael A. Metzger, analysts maintain a generally positive outlook on the stock, with a consensus price target of $42.55. Shares recently traded around $19.04, following a 2.6% gain.
Elmind Capital LP Purchases New Stake in Syndax Pharmaceuticals, Inc. $SNDX
Elmind Capital LP has acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the fourth quarter, purchasing 1,855,000 shares valued at approximately $38,974,000, making it their second-largest holding. Other institutions like Vanguard Group Inc., Goldman Sachs Group Inc., and State Street Corp have also increased their holdings in Syndax Pharmaceuticals, while company insiders have recently sold shares. The company's stock opened at $19.04, has a market capitalization of $1.69 billion, and analysts have a "Moderate Buy" consensus rating with a target price of $42.55.
Syndax Pharmaceuticals Inc (SNDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article from TradingKey provides an overview of Syndax Pharmaceuticals Inc (SNDX), including its current stock price and market capitalization. It highlights that relevant revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page serves as a placeholder for financial analysis related to the company's revenue structure.
(SNDX) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily analyzes Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) providing tactical triggers based on volatility zones. It highlights a positive near-term sentiment while noting potential mid-term weakness within a long-term strength context. The analysis includes institutional trading strategies with specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
Syndax Pharmaceuticals Inc (SNDX) Institutional Confidence
Syndax Pharmaceuticals Inc (SNDX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 3.63% quarter-over-quarter, reaching 123.04%. Steven Cohen is the largest institutional shareholder, holding 2.37 million shares, which represents 2.24% of outstanding shares.
Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia
Syndax Pharmaceuticals (SNDX) shares are under renewed focus after positive Phase 1/2 SAVE trial data for its Revuforj-based regimen in acute myeloid leukemia. Despite recent short-term gains, the stock faces a narrative of being 53.8% undervalued with a fair value of $39.50, based on its late-stage pipeline and potential for long-term growth. However, this valuation is highly dependent on the successful progression and adoption of its key therapies, Revuforj and Niktimvo.
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Eventide Asset Management LLC increased its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 25.3% to include 1,238,196 shares valued at $26.01 million. Other institutional investors like Vanguard Group Inc., Bank of America Corp DE, and Qube Research & Technologies Ltd also significantly boosted their holdings. Despite recent insider share sales totalling over $1.3 million, analysts maintain a "Moderate Buy" rating for SNDX with an average price target of $42.55.
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX
Voss Capital LP has acquired a new stake of 125,000 shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) for approximately $2.63 million in the fourth quarter. Other major institutional investors like Vanguard, Goldman Sachs, and Bank of America also increased their holdings. Wall Street analysts maintain a "Moderate Buy" rating for Syndax, with an average target price of $42.55, following a reported narrower-than-expected quarterly loss and significant revenue growth.
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed
Syndax Pharmaceuticals (SNDX) saw a 5.2% increase in its stock price following positive Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in acute myeloid leukemia patients. The trial data, published in the Journal of Clinical Oncology, showed high response rates and deep measurable residual disease negativity, reinforcing Revuforj's potential for label expansion despite a complex safety profile. The company recently secured US$250 million in convertible notes to fund future clinical trials and commercialization efforts.
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX
Rhenman & Partners Asset Management AB recently sold 87,000 shares of Syndax Pharmaceuticals, Inc. (SNDX), reducing its stake by 15.2% to 487,000 shares valued at approximately $10.2 million. Insider selling also occurred, with CMO Nicholas A.J. Botwood and CEO Michael A. Metzger selling shares totaling about $1.34 million in the last quarter. Despite beating earnings estimates with a smaller-than-expected loss of $0.48 per share, revenue fell short of forecasts, and analysts still project a full-year loss for the company.
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options
Syndax Pharmaceuticals' Head of R&D and CMO, Nicholas A.J. Botwood, engaged in an exercise-and-sell transaction, acquiring 53,750 shares through stock options at $13.82 per share and subsequently selling 65,515 shares in open-market transactions for approximately $18 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Botwood retains 60,885 common shares and a substantial number of vested and unvested options.
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares
Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) filed a Rule 144 notice for a proposed sale of 31,235 shares of common stock on June 12, 2026, linked to a stock option exercise, with an indicative aggregate amount of $566,692.87. The filing also disclosed a prior sale of 34,280 shares on June 11, 2026, for $609,434.95 by Nicholas Botwood. Fidelity Brokerage Services LLC is listed as the broker for the transaction.
[144] Syndax Pharmaceuticals Inc SEC Filing
Syndax Pharmaceuticals Inc. has filed a Form 144, indicating a proposed sale of common stock by an affiliate. The filing details the intended disposition of 11,565 shares from an open-market entry, 200 shares from restricted stock vesting, and 22,515 shares from a stock option exercise. This notice serves as a routine disclosure for affiliate resale, with actual sale execution and proceeds expected to be documented in subsequent reports.
Syndax showcases revuforj (revumenib) data at EHA 2026
Syndax Pharmaceuticals presented extensive clinical data for its blood cancer drug, Revuforj (revumenib), at the European Hematology Association (EHA) 2026 Congress. The data highlighted the drug's efficacy in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with specific genetic mutations, showing high remission rates and promising results in real-world settings and as a post-transplant maintenance therapy. These findings underscore Revuforj's potential to significantly improve outcomes for patients with these challenging blood cancers.
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals presented new clinical data for Revuforj® (revumenib), its FDA-approved menin inhibitor, at the European Hematology Association (EHA) 2026 Congress. The data showcased robust activity in multiple acute leukemia subtypes, including high overall response rates and complete remission rates in relapsed/refractory and newly diagnosed patients, both as monotherapy and in combination with other treatments. These findings highlight revumenib's potential to significantly improve patient outcomes and support ongoing pivotal trials for frontline combination therapies.
Syndax Announces Publication of SAVE Data on Revuforj®
Syndax Pharmaceuticals announced the publication of data from its Phase 1/2 SAVE trial in the Journal of Clinical Oncology, demonstrating high response rates for an all-oral regimen of Revuforj® (revumenib) in combination with decitabine/cedazuridine and venetoclax for patients with relapsed/refractory acute myeloid leukemia (AML) with specific genetic mutations. The study highlighted significant overall response rates, complete remission, and instances of MRD negativity, even in heavily pretreated and venetoclax-exposed patients. These findings support further investigation into revumenib combinations for menin-dependent acute leukemias.
SNDX6417984 Bond Coupon Analysis — Rate & Payments
This article provides an analysis of the SNDX6417984 bond issued by Syndax Pharmaceuticals, Inc. It highlights the bond's current coupon rate of 2.25% and specifies that the next interest payment is scheduled for December 15, 2026. The content encourages users to unlock full data for a comprehensive understanding of the bond's payment schedule and coupon details.
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals presented robust data on its FDA-approved menin inhibitor, Revuforj (revumenib), at the European Hematology Association (EHA) 2026 Congress. The presentations highlighted Revuforj's clinical activity across various acute leukemia subtypes and treatment settings, including real-world, post-transplant, and combination therapies, showcasing its potential for deep and durable remissions. Key findings included high overall response rates and complete remission rates in relapsed/refractory patients, as well as significant MRD negativity and promising survival rates.
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals presented extensive data at the EHA 2026 Congress showcasing Revuforj® (revumenib)'s clinical activity across various acute leukemia subtypes and treatment settings. The data highlights robust efficacy in relapsed/refractory and newly diagnosed patients, including high overall and complete response rates, MRD negativity, and promising overall survival post-transplant, reinforcing its potential to transform patient outcomes.
Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031
Syndax Pharmaceuticals has successfully issued $250 million in 2.25% Convertible Senior Notes due 2031 through a private placement with institutional investors, yielding net proceeds of $243 million. These funds are slated for general corporate purposes, including R&D and commercialization activities. The notes have an initial maximum conversion rate of 54.5256 shares per $1,000 principal amount, potentially leading to the issuance of up to 13,631,400 common shares.
[8-K] Syndax Pharmaceuticals Inc Reports Material Event
Syndax Pharmaceuticals Inc. announced that stockholders approved all proposals at their June 10, 2026 annual meeting, including a new 2026 Equity Incentive Plan reserving 7,200,000 shares and a 2026 Employee Stock Purchase Plan. Stockholders also elected directors, gave advisory approval for executive compensation, and ratified the company's independent accounting firm. These approvals signify strong shareholder support for the company's compensation and governance structures.
Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates
This article provides a list of Syndax Pharmaceuticals, Inc. (SNDX) corporate bonds, sorted by yield to worst. It highlights the perceived stability of corporate bonds during market volatility, encouraging investors to review prices, yields, and other relevant statistics. The data includes details on a specific bond issue with maturity in 2031.
Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates
This article provides details on Syndax Pharmaceuticals Inc's corporate bonds, highlighting their stability for investors during market volatility. It lists specific bond information, including yield, price, coupon, maturity date, outstanding amount, and face value, to help investors find reliable investment options.
SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation
Syndax Pharmaceuticals (SNDX) is experiencing strong growth propelled by the clinical success and expanding use of its drug Revuforj in hematology. Recent capital raises are supporting the company's robust R&D efforts and a promising pipeline, including pivotal trials and new indications for NUP98 and IPF. This momentum was highlighted at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026.
Syndax Pharmaceuticals (SNDX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Syndax Pharmaceuticals (SNDX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference 2026, highlighting their robust R&D capabilities and commercialization expertise in hematology, which led to two successful drug launches. The company showcased strong clinical data for Revuforj, especially in maintenance therapy, and discussed an opportunistic, low-cost convertible note to enhance pipeline expansion and ongoing trials. Their financial strategy now includes equity and a synthetic royalty to support investments in new assets and IPF development.
